ESC 365 - The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model

ESC Professional Premium Access

The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model

Session: Molecular cardio-oncology

Topic: Drugs, Drug Targets

Speaker: Ms D. Chen (Newcastle, AU)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Ms Dongqing Chen

University of Newcastle, Newcastle (Australia)

0 follower

5 more presentations in this session

Heart failure stimulates colorectal tumour growth through gut microbial alterations of specific populations

Speaker: Ms S. De Wit (Groningen, NL)

Cardiometabolic rewiring in the context of doxorubicin-induced cardiotoxicity: fuel preference changes from fatty acids to glucose oxidation

Speaker: Doctor G. Guerra (Turin, IT)

Rapamycin ameliorates doxorubicin-induced cardiomyopathy through suppression of RIPK1-independent necroptosis

Speaker: Doctor M. Shimizu (Sapporo, JP)

CaMKIIdelta-mediated SR Ca leak contributes to long-term Doxorubicin-induced cardiotoxicity

Speaker: Miss A. Feder (DE)

Glycogen Synthase Kinase 3 beta confers refractoriness to the microRNA-210-elicited exacerbation of hypoxia-reoxygenation stress-induced apoptotic cell death

Speaker: Doctor G. Marwarha (Trondheim, NO)

Access the full session

Molecular cardio-oncology

Speakers: Ms D. Chen, Ms S. De Wit, Doctor G. Guerra, Doctor M. Shimizu, Miss A. Feder...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources